KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 110 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $489,000 | -98.3% | 46,470 | -97.5% | 0.02% | -98.1% |
| Q4 2020 | $28,217,000 | +20.5% | 1,822,781 | +13.7% | 0.94% | -2.8% |
| Q3 2020 | $23,407,000 | -0.7% | 1,603,253 | +28.9% | 0.96% | -6.2% |
| Q2 2020 | $23,565,000 | +17.3% | 1,244,211 | +19.0% | 1.03% | -11.6% |
| Q1 2020 | $20,085,000 | +109.0% | 1,045,548 | +108.6% | 1.16% | +186.2% |
| Q4 2019 | $9,609,000 | -33.3% | 501,253 | -66.5% | 0.41% | -39.6% |
| Q3 2019 | $14,397,000 | +62.8% | 1,496,583 | +1.4% | 0.67% | +89.3% |
| Q2 2019 | $8,843,000 | +0.4% | 1,476,234 | -2.1% | 0.36% | -0.8% |
| Q1 2019 | $8,807,000 | -35.5% | 1,508,094 | +3.5% | 0.36% | -46.6% |
| Q4 2018 | $13,647,000 | +15.5% | 1,456,473 | +109.8% | 0.67% | +54.6% |
| Q3 2018 | $11,820,000 | +23.9% | 694,068 | +23.6% | 0.43% | +20.6% |
| Q2 2018 | $9,537,000 | – | 561,317 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |